Alligator Bioscience AB: Interim report January-March 2021

                                                                                                          
High activity during the first quarter
"So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year."
Malin Carlsson, Interim CEO Alligator Bioscience AB
SIGNIFICANT EVENTS JANUARY-MARCH
Pipeline:
New preclinical data were released in an abstract for a poster presentation at the AACR Annual Meeting 2021, demonstrating that mitazalimab synergizes with chemotherapy.
Company:
Søren Bregenholt was appointed as new CEO to strengthen Alligator's business development activities and clinical progress on an international level.
Oversubscribed rights issue generated proceeds of SEK 86 million before transaction costs.

Related Keywords

Sweden ,Stockholm ,Hans Peter Ostler ,Malin Carlsson ,Marie Svensson ,Veronica Wallin ,Anders Ekblom ,Graham Dixon ,Nomination Committee ,Aptevo Therapeutics Inc ,Shanghai Henlius Biotech Inc ,Annual General ,Annual General Meeting ,Aptevo Therapeutics ,Shanghai Henlius Biotech ,Nasdaq Stockholm ,Alligator Bioscience ,ஸ்வீடந் ,ஸ்டாக்‌ஹோல்ம் ,மாலின் கார்ல்சன் ,மேரி ஸ்வெந்‌ஸந் ,வெரோனிகா வாலின் ,கிரஹாம் டிக்சன் ,நியமனம் குழு ,ஆண்டு ஜநரல் ,ஆண்டு ஜநரல் சந்தித்தல் ,நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,முதலை உயிர் அறிவியல் ,